Activity of mRNA COVID-19 vaccines in patients with lymphoid malignancies
Jennifer L. Crombie(Dana-Farber Cancer Institute), Nicolas C. Issa(Dana-Farber Cancer Institute), Yasmeen Senussi(Brigham and Women's Hospital), Jennifer R. Brown(Dana-Farber Cancer Institute), Michaël Desjardins(Centre Hospitalier de l’Université de Montréal), Tal Gilboa(Brigham and Women's Hospital), Natalie Izaguirre(Dana-Farber Cancer Institute), Amy C Sherman(Dana-Farber Cancer Institute), Jonathan Krauß, Philippe Armand(Harvard University), Matthew S. Davids(Dana-Farber Cancer Institute), Christine E. Ryan(Dana-Farber Cancer Institute), Peter Baker(Dana-Farber Cancer Institute), Chi‐An Cheng(Brigham and Women's Hospital), David R. Walt(Brigham and Women's Hospital), Lindsey R. Baden(Brigham and Women's Hospital), Bruce Bausk, Mikaela M. McDonough(Dana-Farber Cancer Institute), Rebecca L. Zon(Brigham and Women's Hospital)
Cited by 24
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k